Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. This study aims to investigate whether chloride channel 2 (ClC-2) is involved in high fat diet (HFD)-induced NAFLD and possible molecular mechanisms. Methods: ClC-2 expression was liver-specifically downregulated using adeno-associated virus in C57BL/6 mice treated with a chow diet or HFD for 12 weeks. Peripheral blood and liver tissues were collected for biochemical and pathological estimation respectively. Western blotting was applied to detect the protein expressions of lipid synthesis-related enzymes and the phosphorylated level of IRS-1, Akt and mTOR. Results: ClC-2 mRNA level was significantly increased in patients with non-alcoholic steatohepatitis, which positively correlated with the plasma levels of alanine transaminase (ALT), aspartate transaminase (AST) and insulin. Knockdown of ClC-2 in liver attenuated HFD-induced weight gain, obesity, hepatocellular ballooning, and liver lipid accumulation and fibrosis, accompanied by reduced plasma free fatty acid (FFA), triglyceride (TG), total cholesterol (TC), ALT, AST, glucose and insulin levels and homeostasis model of insulin resistance (HOMA-IR) value. Moreover, HFD-treated mice lacking ClC-2 showed inhibited hepatic lipid accumulation via regulating lipid metabolism through decreasing sterol regulatory element binding protein (SREBP)-1c expression and its downstream targeting enzymes such as fatty acid synthase (FAS), HMG-CoA reductase (HMGCR) and acetyl-Coenzyme A carboxylase (ACCα). In addition, in vivo and in vitro results demonstrated that ClC-2 downregulation in HFD-treated mice or HepG2 cells increased the sensitivity to insulin via activation of IRS-1/Akt/mTOR signaling pathway. Conclusion: Our present study reveals a critical role of ClC-2 in regulating metabolic diseases. Mice lacking ClC-2 are associated with a remarkably beneficial metabolic phenotype, suggesting that decreasing ClC-2 may be an attractive therapeutic strategy for the treatment of NAFLD.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic component of metabolic syndrome not due to excess alcohol consumption, and is the most common cause of chronic liver disease in the world [1] . NAFLD encompasses a spectrum of disorders ranging from simple hepatic steatosis, which is characterized by lipid accumulation in hepatocytes, to non-alcoholic steatohepatitis (NASH), which can further develop to cirrhosis and hepatocellular carcinoma [2, 3] . Moreover, NAFLD and NASH confer an increased risk of cardiovascular diseases [4] . Despite many factor including oxidative stress, fatty acid syntheses and inflammation have been suggested to be implicated in NAFLD [5] , the precise mechanism of the onset and development of NAFLD remains to be clearly defined.
The prevailing theory of NAFLD pathogenesis is commonly based on the 'double-hit' hypothesis [6] . Insulin resistance (IR) and abnormal hepatocellular lipid accumulation represents the 'first hit', which in turn trigger "second hit" such oxidative stress, inflammation, apoptosis and fibrosis, thus leading to the occurrence of NASH. Therefore, targeting IR and lipid dysregulation that occurs with progressive NAFLD will be extremely important for developing more sophisticated treatment options for NAFLD patients. IR, the pivotal mechanism in primary NAFLD, is defined as decreased sensitivity to insulin and associated with defective insulin signaling transduction, uptake of fatty acids by the liver, and synthesis of triglycerides (TG) [7] .
Chloride ions (Cl -) are common and abundant anions in organism, regulating a variety of physiological and pathological processes [8] . Increasing lines of evidences have suggested that dysregulated intracellular Cl -level is associated with vascular inflammation, hypertension, lipid accumulation and atherosclerosis [9] [10] [11] . Chloride channels (ClCs) function as a kind of permeable channel or protein, which are encoded and regulated by the genes of ClC family [12] . ClC-2, a member of ClCs family, is almost ubiquitously expressed, including in the liver [12, 13] . Recently, ClC-2 attracted increasing attention because ClC-2 has been implicated in several diseases, such as cystic fibrosis, leukemia and diabetes mellitus [12, 14] . Importantly, fatty acids can activate human ClC-2 Cl -channel [15] , further supports the involvement in metabolic disorders. However, the expression pattern and functional role of ClC-2 in NAFLD remain unknown. The aim of this study was to investigate the effect of ClC-2 on NAFLD and examine the underlying mechanisms.
Materials and Methods

Materials
Antibodies targeting sterol regulatory element binding protein (SREBP)-1c, fatty acid synthase (FAS), HMG-CoA reductase (HMGCR) and acetyl-Coenzyme A carboxylase (ACCα) were purchased from Biosynthesis Biotechnology (Beijing, China). P-Akt (Ser473), Akt, p-mTOR (Ser2448), mTOR and β-actin antibodies were from Cell Signaling Technology (CA, USA). ClC-2, p-insulin receptor substrates 1 (p-IRS-1) (Tyr608/612), p-IRS-1 (Ser307) and IRS-1 were obtained from Abcam (MA, USA). SuperScript III FirstStrand Synthesis system, Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FBS), penicillin, streptomycin and lipofectamine 2000 reagent were obtained from Invitrogen (CA, USA).
Human studies
In this study, 14 subjects without NASH (near-normal liver histology, NNLH) and 31 NASH patients were recruited, which was approved by the Cangzhou Central Hospital Human Research Ethics Committee. Informed consent was obtained from each subject and all protocols were carried out in accordance with the guidelines of National Health and Medical Research Council of China. All subjects were received routine clinical assessment, including radiologic, hematologic, biochemical, and serologic testing. Male patients with daily alcohol consumption of > 30 g and female patients > 20 g were ruled out. Under laparoscopic guidance, a percutaneous core liver biopsy was performed with a 15-gauge biopsy device. Plasma samples were collected following an overnight fast on the day of liver biopsy. Patients were considered as NASH 
Animals
Animal study was approved by the Institutional Animal Care and Use Committee of Cangzhou Central Hospital and carried out in accordance with the Guide for the Care and Use of Laboratory Animals of Cangzhou Central Hospital. 90 male C57BL/6 mice were purchased from the Jackson Laboratory (ME, USA) and maintained on a 12 h/12 h light-dark cycle with free access to water and to the diets according to their treatment. The mice were randomly divided into 4 groups as follows: chow diet with adeno-associated virus (AAV)-null (n=15), chow diet with AAV-sh-ClC-2 (n=15), high fat diet (HFD) with AAV-null (n=30) and high fat diet with AAV-sh-ClC-2 (n=30). To knockdown ClC-2 expression specifically in liver, a small hairpin RNA sequence targeting mouse ClC-2 was subcloned into a specialized AAV8 vector provided by Addgene (MA, USA). AAV8 viral particles carrying an empty vector (AAV-null) were used as controls. At 10 weeks of age, mice were injected intravenously with AAV-sh-ClC-2 or AAV-null at a dose of 1×10 11 genome copies per mouse and then received a chow diet or HFD (45% kcal fat, D12451, Research Diets, Inc., NJ, USA) for 12 weeks.
Blood measurement
Plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), high-density lipoprotein cholesterol (HDL-cholesterol), low-density lipoprotein cholesterol (LDL-cholesterol) (all from Jian Cheng Biological Engineering Institute, Nanjing, China), TG (Cayman, MI, USA), total cholesterol (TC), free fatty acids (FFA) (Wako Diagnostics, VA, USA), glycerol (Sigma, MO, USA) and lactate (Roche Diagnostics, Mannheim, Germany) were determined by biochemical assays. Blood glucose and plasma insulin measurements were performed in 10 h overnight-fasted mice using OneTouch Ultra Test Strips (Lifescan, BC, Canada) and Insulin ELISA Kit (Chrystal Chem, IL, USA), respectively. The homeostasis model assessment of IR (HOMA-IR) index was calculated as fasting blood glucose × fasting insulin/22.5. Glucose tolerance test (GTT) was monitored in 10 h fasted mice after a 12-week HFD. Mice were intraperitoneally injected with 1.5 g glucose/kg body weight. Insulin tolerance test (ITT) was performed with non-fasted mice after intraperitoneal injection of insulin (0.5 IU/kg body weight).
Determination of biochemistry in liver tissue
Mouse livers were harvested at the end of the experimental period. Liver homogenates were prepared in a 10-fold volume (v/w) anhydrous alcohol, followed by centrifugation at 15000 rpm, 4°C for 15 min. The supernatant was collected for TC and TG determination using the same method in plasma measurement. Protein concentrations of liver tissue were quantified using the Enhanced BCA Protein Assay Kit (Beyotime, Jiangsu, China). Hepatic TC and TG were normalized to total proteins of tissue homogenates.
QRT-PCR
Total RNA (1 μg) from human liver tissues was isolated using the RNeasy Mini kit (Qiagen, CA, USA) and was reverse-transcribed using the SuperScript III First-Strand Synthesis system. QRT-PCR was performed using Fast SYBR ® Green Master Mix Kit (Applied Biosystems, CA, USA) with an ABI Prism 7300 Fast Real-Time PCR system (Applied Biosystems). The ClC-2 mRNA expression was normalized to the mRNA levels of GAPDH. The specific primer sequences used for the amplification were as follows: ClC-2, 5'-CACAGGTGGTGGCATTGTTG-3' and 5'-GGACTTTCACACCCTGTGCT-3'; GAPDH, 5'-GGGCACGAAGGCTCATCATT-3' and 5'-AGAAGGCTGGGGCTCATTTG-3'.
Western blotting
Liver tissues or HepG2 cells were washed with cold phosphate buffered solution 3 times and lysed in RIPA buffer (Beyotime) containing 1% protease inhibitor cocktail (Roche). After determination of protein concentrations, equal protein were separated on 8% or 10% Tris-HCL polyacrylamide gel and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, MA, USA). Membranes were blocked by 5% nonfat milk for 1 h, followed by incubation with primary antibodies at 4°C overnight. At the end of incubation period, the membranes were incubated with the secondary peroxidase-conjugated antibodies (goat anti- 
Body composition
Mice were under 4% chloral hydrate in anesthesia and analyzed for body mass composition through micro-computed tomography (micro-CT, INVEON, Siemens, TN, USA). Body mass composition was calculated using accompanied software.
Histological examination
The white adipose tissue (WAT), brown adipose tissue (BAT) and liver tissues were resected, dehydrated, infiltrated with paraplast embedding media (Sigma), fixed in 10% formalin solution, embedded in fresh paraffin and subsequently sliced into 5-μm sections. Sections were stained with hematoxylin-eosin (HE), Oil Red O and masson trichrome. Images were captured using a Zeiss Axioplan2 fluorescence microscope (München, Germany). The mean diameter of adipocytes was calculated using the "Count/Size" function of Image-pro software (Media Cybernetics, MD, USA). All histological data were obtained by independent experimenters who were blinded to the physical outcome and other biological information of each sample.
Metabolic cages
Mice were individually housed in metabolic cages (Comprehensive Laboratory Animal Monitoring System, Columbus Instruments, OH, USA) for 24. Food and water intake was measured. The respiratory exchange ratio (RER) was calculated (VCO 2 /VO 2 ).
Cell culture
HepG2 cells were obtained from the American Type Culture Collection (ATCC, VA, USA) and cultured in DMEM supplemented with 10% FBS, antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin at 37°C in a 95:5 air/CO 2 humidified atmosphere.
ClC-2 siRNA transfection
The stealth siRNA duplex oligoribonucleotides against human ClC-2 (5'-CUACTACCATCATTCAUAACGU-3') was synthesized and purchased from FulenGen (Wuhan, China). HepG2 cells were transfected with ClC-2 siRNA or negative siRNA using lipofectamine2000 reagent for 48 h before insulin (Sigma) treatment.
Adenovirus infection
Human ClC-2 cDNA was obtained from Vigene Bioscience (Shandong, China) and cloned into pAdTrack-CMV (Invitrogen). The recombinant plasmid was linearized by PacI digestion and then transfected into 293A cells with lipofectamine 2000 reagent to generate recombinant adenovirus. After amplification and purification, the titers of ClC-2 adenovirus (Ad-ClC-2) were assessed. An adenovirus bearing LacZ (Ad-Lacz, Clontech, CA, USA) was used a negative control. To make ClC-2 overexpression in HepG2 cells, cells were infected with Ad-ClC-2 or Ad-Lacz in FBS-free DMEM for 6 and then transferred into complete medium and cultured for 48 h.
Statistical analysis
Data were expressed as mean±SEM. n value represented the number of independent experiments or mouse. The correlation between ClC-2 expression and ALT, AST or insulin levels was examined by the Pearson correlation test. The statistical significance of differences between two groups was analyzed by Student t-test. Comparisons among multiple groups were performed by one-way ANOVA with post hoc Tukey's test. P<0.05 was considered to be statistically significant.
Results
Increased ClC-2 expression correlated with plasma ALT, AST and insulin levels in NASH patients
Compared with NNLH individuals with mildly elevated plasma liver enzymes, patients with NASH significantly increased the value of body mass index and waist circumference (Fig. 1B-D) . These data suggest that ClC-2 level is reduced during liver injury and correlated with plasma ALT, AST and insulin levels.
Knockdown of ClC-2 inhibited HFD-induced obesity
Adiposity is the major feature of IR and NAFLD. To investigate whether ClC-2 is involved in NAFLDassociated obesity, 10-week old C57BL/6 mice were infected with liver specific AAV-sh-ClC-2 followed by a 12-week HFD. Consistent with increased ClC-2 level in NASH patient, ClC-2 expression in liver of HFD mice was also significantly increased. Injection of AAV-sh-ClC-2 inhibited the increased expression of ClC-2 ( Fig. 2A) . Although ClC-2 inhibition had no effect on body weight under chow diet treatment, mice lacking ClC-2 in liver showed less weight gain after 3-12 weeks of the HFD treatment (Fig. 2B) . AAVnull-treated HFD mice gained 13.7 g weight due to an increase of 13.1 g fat mass, while ClC-2 knockdown mice only gained 9.3 g weight due to an increase of 8.8 g fat mass. This supported that the reduction in body weight was associated a decrease of 4.3 g fat mass. No significant difference was observed in lean mass (Fig. 2C) . Moreover, inguinal WAT (iWAT), gonadal WAT (gWAT) and interscapular BAT (iBAT) were all significantly reduced by 32.8%, 53.6% and 39.1%, respectively, in AAV-sh-ClC-2 treated HFD mice when compared with AAV-null control (Fig. 2D) . The morphological and histological changes in the adipose tissue were ameliorated in ClC-2 knockdown mice under HFD treatment, as evidenced by reduced adipocyte diameters in iWAT and iBAT (Fig. 2E-H) . In addition, specific knockdown of ClC-2 in liver markedly inhibited HFD-induced the increase of plasma FFA, TG and TC levels, but produced no effect on glycerol and lactate levels (Fig. 2I-M) . 
Effects of ClC-2 inhibition on metabolic parameters and regulators
To elucidate the mechanism why ClC-2 knockdown inhibits HFD-induced obesity, the whole-body metabolic parameters such as food and water intake, and RER were measured. Although a significant change in food intake was found between chow and HFD treatment, it did not differ before and after ClC-2 inhibition in HFD mice (Fig. 3A) . Similarly, water intake remained unchanged among four groups (Fig. 3B) . Despite similar food and water intake, AAV-sh-ClC-2 treatment resulted in an increase of RER compared with AAV-null-treated HFD mice (Fig. 3C) . Furthermore, the protein expressions of several lipid synthesis-related enzymes in liver were detected by western blotting. The hepatic protein expressions of sterol regulatory element binding protein (SREBP)-1c, fatty acid synthase (FAS), HMG-CoA reductase (HMGCR) and acetyl-Coenzyme A carboxylase (ACCα) were markedly increased in HFD mice than in chow diet mice. However, knockdown of ClC-2 reversed these changes (Fig. 3D-H) .
ClC-2 downregulation ameliorated liver injury
To investigate the effect of ClC-2 inhibition on hepatic injury during NAFLD, two hepatic enzymes (ALT and AST) that reflect the degree of liver damage were first examined. The results showed that the plasma ALT and AST levels in HFD mice were higher than those of chow diet mice, which was markedly lowered after AAV-sh-ClC-2 treatment (Fig. 4A and B) . Consis- tent with the changes of plasma lipids, hepatic TC and TG levels were both increased after HFD treatment, while ClC-2 downregulation was associated with decreased hepatic lipids accumulation ( Fig. 4C and D) . Furthermore, the liver weight and the ratio of liver weight to body weight were higher in HFD mice than in chow diet mice. However, we noticed that AAV-sh-ClC-2-treated mice gained less liver weight than AAV-null-treated mice after HFD feeding ( Fig. 4E and F). As displayed in Fig.  4G , no significant differences in liver pathological characteristics were observed between the types of mice fed chow diet. AAV-null treated HFD mice showed marked hepatocyte ballooning and inflammatory cell infiltration, which was significantly attenuated by ClC-2 inhibition. Similar to the effect on TC and TG levels, oil red O staining revealed that AAVsh-ClC-2 treatment also decreased HFD-induced the deposition of lipid droplets in hepatocytes (Fig. 4H) . Additionally, masson trichrome staining showed lower deposition of collagen fibrils in liver in AAV-shClC-2-treated mice than in AAV-null-treated mice after HFD treatment (Fig. 4I) .
ClC-2 lacking attenuated HFD-induced insulin resistance
Glucose metabolism dysfunction and IR are typical clinical symptoms of NAFLD [16] . Mice fed with HFD showed markedly higher fasting blood glucose and insulin. Compared with AAV-null-treated HFD mice, knockdown of ClC-2 displayed reduced blood glucose and insulin ( Fig. 5A and B) . Furthermore, systemic IR was evaluated using the HOMA-IR index. As shown in Fig. 5C , HFD treatment induced a significant increase of IR, as indicated by the high HOMA-IR value. However, HFD mice lacking ClC-2 showed a marked decrease in HOMA-IR value compared with those of AAV-null-treated HFD mice. GTT and ITT revealed that there were no differences between AAV-null-treated mice and AAV-sh-ClC-2-treated mice on chow diet ( Fig. 5D and E) . However, on HFD, AAV-sh-ClC-2-treated mice cleared plasma glucose more efficiently after glucose, as well as after insulin intraperitoneal injection ( Fig. 5F and G). These results suggest that ClC-2 inhibition can improve glucose clearance and insulin sensitivity.
ClC-2 mediated hepatic insulin signaling pathway
To assess the underlying mechanisms by which knockdown of ClC-2 prevents IR, the activation of IRS-1 and downstream pathways were determined. Western blotting showed that AAV-sh-ClC-2-treated HFD mice activated insulin signaling, as evidenced by mildly increased 
phosphorylation of IRS-1 (Tyr608), Akt (Ser473) and mTOR (Ser2448) and reduced phosphorylation of IRS-1 (Ser307) in liver. Moreover, an acute intraperitoneal injection of insulin dramatically induced insulin signaling activation, which was further enhanced after ClC-2 downregulation (Fig. 6A-D) .
To support the in vivo findings Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry reported above, human HepG2 cells were exposed to ClC-2 siRNA followed by insulin treatment for different time points as indicated. Our results showed insulin induced phosphorylation of IRS-1 (Tyr608), Akt (Ser473) and mTOR (Ser2448) in negative siRNAtreated cells. These inductions were maintained over a range of indicated time points. Importantly, downregulation of ClC-2 significantly further promoted IRS-1/Akt/mTOR signaling activation (Fig. 6E-G) . Although insulin also triggered IRS-1 (Tyr612), Akt (Ser473) and mTOR (Ser2448) phosphorylation in Ad-ClC-2-treated cells, the extent was significantly less than those of Ad-Lacz-treated cells (Fig. 6H-J) .
Discussion
NAFLD has been regarded as a serious public health problem that affects more than 40% of population in some developed countries [3] . Unfortunately, there is no pharmacological agent currently available for the treatment of NAFLD. It is recently thought that the methods for treating NAFLD include exercise, rational diet and medicines (fibrate, statins and metformin) [2, 5] . However, it still cannot reach consensus on effective drug therapies due to some contraindications and adverse effects [17] . Our present study demonstrates that mice lacking ClC-2 are associated with a remarkably beneficial metabolic phenotype. The results Here, our clinical data demonstrated the critical role of ClC-2 in NAFLD, as evidenced by increased level of ClC-2 in NASH patients compared with NNLH patients. Importantly, the extent of increased ClC-2 expression in liver was positively associated with plasma ALT, AST and insulin levels. Despite the correlation coefficients were not ideal due to relatively small sample amount, they were considered to be statistically significant. Notably, there is a limitation in our present study because of lack of comparison between NASH patient and healthy individuals. In prior to this study, few studies were performed to explore the association between ClC-2 and metabolic diseases. Although a recent study identifying the activation site on ClC-2 induced by fatty acids [15] , the functional role of ClC-2 in metabolic diseases is still unknown. Until now, a study on diabetes mellitus was found. Pan et al. found that high glucose stimulation inhibited keratinocyte migration through decreasing ClC-2 expression, indicating ClC-2 plays a key role during delayed wound healing process [14] . This finding contrasts with our observations in the changes of ClC-2 expressions. The variations in cell types, tissue location and disease state may explain this difference.
Obesity is a major heath issue worldwide and is a complex metabolic syndrome associated with IR and NAFLD [18] . Our study found that HFD mice lacking ClC-2 were resistant to obesity, and leaner than AAV-null-treated HFD mice, which may be resulted from reduced fat mass. Although the food intake was mildly fewer in AAV-sh-ClC-2 HFD mice than in AAV-null HFD mice, it did not fully account for the reduced fat mass observed in AAV-shClC-2 HFD mice. However, RER was significantly elevated after inhibition of ClC-2, indicating the reduced adipose mass may be associated with increased carbohydrate combustion. It has been suggested that high plasma level of FFA contribute to development of NASH [19] . Infusion of TG emulsions to rapidly increase FFA level would result in a reduction of insulin sensitivity [20] . Excessive generation of circulating FFA from WAT can be subsequently absorbed by liver where FFA transforms into TG and bioactive lipid, leading to cause IR and NAFLD [7, 21] . In this study, the results showed that plasma levels of FFA, TG and TC were elevated in HFD mice, which were inhibited after ClC-2 downregulation. But ClC-2 knockdown produced no effect on the increased levels of glycerol and lactate.
According to the aforementioned 'double-hit' hypothesis, lipid accumulation plays an important role in the 'first hit', whereas the 'second hit' is in combination with oxidative stress and inflammation that eventually leads to liver fibrosis [6] . In the current study, we provided the first evidence that ClC-2 inhibition prevented HFD-induced hepatic lipid accumulation, inflammation and fibrosis. In addition to liver morphology, the hepatic function was also determined, as suggested by the reduced plasma levels of ALT and AST in AAV-sh-ClC-2 HFD mice compared with the AAV-null HFD mice. To investigate the mechanism whereby ClC-2 knockdown inhibits lipid accumulation, several lipid metabolism-related enzymes were detected. SREBP-1c is an important transcription factor, regulating lipid synthesis and fatty acid metabolism in liver [22] . Moreover, SREBP-1c also regulates several genes involved in the de novo pathway, such as FAS and ACCα, mediating hepatic synthesis of fatty acids, TG and cholesterol [23] . In the way of cholesterol metabolism, HMGCR is a crucial enzyme in the synthesis process of cholesterol [23] . Our results found that HFD mice lacking ClC-2 showed suppressed de novo lipid and cholesterol synthesis in the liver by inhibiting the protein expressions of SREBP-1c, FAS, ACCα and HMGCR.
Our data also demonstrated that knockdown of ClC-2 in HFD mice decreased HOMA-IR value and attenuated whole-body glucose intolerance and IR. IR, besides hepatic lipid accumulation in the 'first hit', is also the first step towards NAFLD [6] . Insulin functions as an important role in regulating hepatic glycogen synthesis and glucose homeostasis [16] . IRS-1 is the major insulin receptor effector that responsible for the transduction of insulin signaling. Upon the binding of insulin to insulin receptor, IRS-1 is phosphorylated at Tyr608/612, leading to insulin pathway activation [16, 24] . On the contrary, phosphorylation of IRS-1 at Ser307/312 is considered a negative feedback marker that blocks insulin signaling, causing glucose uptake impairment and IR [25] . Furthermore, the Akt pathway is thought to be a critical component of insulin signaling cascade, and it is mainly activated at Ser473 [18] . Phosphorylation of Akt can stimulate mTOR by phosphorylating it at Ser2448. Multiple evidences have suggested that dysregulation of the Akt/mTOR signaling pathway is the major molecular mechanism underlying the metabolic dysfunctions such as NAFLD [26] . In the present study, we showed that hepatic ClC-2 deficiency in HFD mice enhanced phosphorylation of IRS-1 at Tyr608 as well as further inhibited Ser307 phosphorylation induced by acute intraperitoneal injection of insulin. Additionally, inhibition of ClC-2 expression in HepG2 cells promoted insulin-induced the activation of IRS-1/Akt/mTOR signaling pathway, whereas ClC-2 overexpression exerted the opposite effects.
Conclusion
Our study has revealed a critical involvement of ClC-2 in regulating metabolic disorders. Downregulation of ClC-2 alleviates HFD-induced obesity, hepatic lipid accumulation, glucose intolerance and IR via strengthening IRS-1/Akt/mTOR signaling pathway. These findings indicate that inhibition of ClC-2 may be a potentially powerful therapeutic strategy for the patients with NAFLD.
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